Page last updated: 2024-11-05

pyrrolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Pyrrolidine is a five-membered saturated heterocyclic amine, a colorless liquid with an ammonia-like odor. It is a common structural motif in many natural products and pharmaceuticals. The compound is synthesized by various methods, including the reduction of pyrrole, the ring-closing metathesis of dienes, and the reaction of 1,4-dichlorobutane with ammonia. Pyrrolidine is a versatile building block for organic synthesis and is used as an intermediate in the production of various pharmaceutical compounds. It exhibits biological activity, including antimicrobial, anti-inflammatory, and analgesic effects. It is also studied for its potential applications in various fields, such as materials science, agriculture, and medicinal chemistry. The importance of pyrrolidine lies in its versatility, its presence in many naturally occurring compounds, and its potential for developing new drugs and materials.'

Cross-References

ID SourceID
PubMed CID31268
CHEMBL ID22830
CHEBI ID33135
MeSH IDM0101472

Synonyms (84)

Synonym
brn 0102395
1-azacyclopentane
un1922
ai3-24117
einecs 204-648-7
nsc 62781
ccris 6688
fema no. 3523
pyrrolidine ring
hsdb 120
prolamine
tetrahydropyrrole
wln: t5mtj
perhydropyrrole
azolidine
nsc-62781
azacyclopentane
butylenimine
nsc62781
pyrrole, tetrahydro-
tetramethylenimine
CHEBI:33135 ,
UPCMLD00WV-121
pyrrolidine ,
123-75-1
inchi=1/c4h9n/c1-2-4-5-3-1/h5h,1-4h
pyrrolidine, >=99%
pyrrolidine, 99%
pyrrolidine, >=99.5%, purified by redistillation
NCIOPEN2_007788
tetrahydropyrrol
CHEMBL22830 ,
tetramethyleneimine
FT-0658759
P0576
bdbm50026437
AKOS000119098
A805120
tetrahydro pyrrole
pyrrolidin
pyrrolidinepyrrolidine
pyrrolidine [un1922] [flammable liquid]
lju5627fyv ,
5-20-01-00162 (beilstein handbook reference)
ec 204-648-7
unii-lju5627fyv
pyrrolidine [hsdb]
pyrrolidine [mi]
pyrrolidine [fhfi]
42403-25-8
pirrolidine
pyrrollidine
pyrolidine
pyrroldine
pyrollidine
pyrrolodine
DTXSID3059559 ,
STR00030
un 1922
mfcd00005249
F2190-0325
pyrrolidine, analytical reference material
pyrrolidine, puriss. p.a., >=99.0%
pyrrolidine, fg
fema 3523
Z57834050
pyrrolidine - ht phase at 207k
pyrrolidine - ht phase at 165k
pyrrolidine - low temperature phase at 205k
pyrrolidine lt phase at 205k
pyrrolidine - low temperature phase at 135k
pyrrolidine lt phase at 135k
pyrrolidine - high temperature phase at 207k
pyrrolidine - high temperature phase at 165k
Q408898
AMY10044
14-pyrrolidine
(s)-pyrrolidine
STL182845
pyrrolidine, distilled in glass
89014-29-9
dtxcid6033796
pyrrole, tetrahydro
EN300-18294

Research Excerpts

Overview

Pyrrolidine-2 is a more potent and specific cPLA(2)α inhibitor than MAFP and AACOCF3. It represents an excellent pharmacological tool to investigate the biosynthesis and biological roles of cancer.

ExcerptReferenceRelevance
"Pyrrolidine-2 is a more potent and specific cPLA(2)α inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of cancer. "( Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells.
Gunasekaran, P; Kannan, S; Sundarraj, S; Thangam, R, 2012
)
1.82

Pharmacokinetics

ExcerptReferenceRelevance
" "Right Box" analysis of cassette dosing screening pharmacokinetic data was used to rapidly categorize the compounds."( Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
Andrews, DM; Barnes, MC; Dowle, MD; Hind, SL; Johnson, MR; Jones, PS; Mills, G; Pateman, TJ; Patikis, A; Redfern, TJ; Robinson, JE; Slater, MJ; Trivedi, N, 2003
)
1.76
" In vivo pharmacodynamic properties (parasite clearance time, parasite reduction ratio, dose and regimen determination) against multidrug resistant (MDR) rodent malaria parasite and toxicological parameters (median lethal dose, liver function test, kidney function test) were also investigated."( Pyrrolidine-Acridine hybrid in Artemisinin-based combination: a pharmacodynamic study.
Batra, S; Biswas, S; Chauhan, BS; Gunjan, S; Pandey, SK; Singh, S; Singh, SK; Srivastava, K; Tripathi, R, 2016
)
1.88
" As such, the purpose of this study was to examine the pharmacokinetic profile of the 'bath salts' in a pregnancy model."( The pharmacokinetic profile of synthetic cathinones in a pregnancy model.
Brown, SD; Keasling, R; Kochelek, K; Pond, BB; Strange, LG, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs."( Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2.
Hattori, K; Koyama, S; Nishio, M; Okitsu, O; Sakane, K; Seki, J; Tabuchi, S; Taniguchi, K, 2005
)
0.84
" Further modification toward improvement of the bioavailability provided (R)-1-(1-((6-fluoronaphthalen-2-yl)methyl)pyrrolidin-3-yl)-3-(2-(2-hydroxyethoxy)phenyl)urea 32 (IC(50)=1."( Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.
Imaoka, T; Inoue, H; Iura, Y; Kubota, H; Morihira, K; Morokata, T; Nitta, A; Ohta, M; Sato, I; Takahashi, T; Takeuchi, M; Tsukamoto, S, 2012
)
0.38
" Furthermore, this compound showed good oral bioavailability (F=54%) in monkeys."( A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
Aonuma, M; Chiba, J; Iigo, Y; Iimura, S; Machinaga, N; Muro, F; Nakayama, A; Setoguchi, M; Sugimoto, Y; Taira, T; Takashi, T; Takayama, G; Watanabe, T; Yokoyama, M; Yoneda, Y, 2013
)
0.39
" Although it holds promise to be a first-in-class Env-targeted entry inhibitor for the clinic, issues with bioavailability relegate its use to salvage therapies only."( Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
Cocklin, S; Karadsheh, R; Meuser, ME, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" "Right Box" analysis of cassette dosing screening pharmacokinetic data was used to rapidly categorize the compounds."( Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
Andrews, DM; Barnes, MC; Dowle, MD; Hind, SL; Johnson, MR; Jones, PS; Mills, G; Pateman, TJ; Patikis, A; Redfern, TJ; Robinson, JE; Slater, MJ; Trivedi, N, 2003
)
1.76
" Members of this class of N-alkylpyrrolidines demonstrate potent and highly selective partial agonism of the progesterone receptor, and one of these analogs was shown to be efficacious upon oral dosing in the OVX rat model of estrogen opposition."( Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.
Bray, JD; Duraiswami, C; Frazee, JS; Glace, LE; Grygielko, ET; Hoang, TH; Laping, NJ; Lapinski, L; Madauss, KP; Thompson, SK; Trizna, W; Washburn, DG; Williams, SP, 2009
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
saturated organic heteromonocyclic parent
pyrrolidinesAny of a class of heterocyclic amines having a saturated five-membered ring.
azacycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID661629Superoxide release activity in potassium phosphate buffer at pH 7.4 and 25 uM after 30 mins by luminol-based colorimetric assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, reactive oxygen species generation and copper-mediated nuclease activity profiles of 2-aryl-3-amino-1,4-naphthoquinones.
AID30382Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1419135Covalent reactivity with N-alpha-acetyl-L-lysine assessed as half life2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
AID701844Dissociation constant, pKa of the compound2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1081643Phytotoxicity against Echinochloa crus-galli (barnyard grass) assessed as mortality measured after 3 days at 5 mg/ml by foliar spraying2010Journal of agricultural and food chemistry, Sep-22, Volume: 58, Issue:18
Phytotoxicity of sarmentine isolated from long pepper (Piper longum) fruit.
AID30521Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -6 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID661627Hydrogen peroxide release activity in potassium phosphate buffer at pH 7.4 after 60 mins by xylene-orange based colorimetric assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis, reactive oxygen species generation and copper-mediated nuclease activity profiles of 2-aryl-3-amino-1,4-naphthoquinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (569)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (9.67)18.7374
1990's20 (3.51)18.2507
2000's163 (28.65)29.6817
2010's282 (49.56)24.3611
2020's49 (8.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.69 (24.57)
Research Supply Index6.37 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index111.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.17%)5.53%
Reviews17 (2.91%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other566 (96.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]